Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT‐2)

Use of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma

(2020) Joshua N. Herb et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit

(2019) Nicholas D. Klemen et al.   JOURNAL OF SURGICAL ONCOLOGY

Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND).

(2019) Zeynep Eroglu et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

(2019) Ulrike Leiter et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations

(2018) Daniëlle Verver et al.   EUROPEAN JOURNAL OF CANCER

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update

(2018) Sandra L. Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma

(2018) Tina J. Hieken et al.   ANNALS OF SURGICAL ONCOLOGY

Updates in adjuvant systemic therapy for melanoma

(2018) Minyoung Kwak et al.   JOURNAL OF SURGICAL ONCOLOGY

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma

(2017) Roberto A. Leon-Ferre et al.   MELANOMA RESEARCH

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Enigma of Regional Lymph Nodes in Melanoma

(2017) Daniel Coit   NEW ENGLAND JOURNAL OF MEDICINE

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

(2017) Mark B. Faries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

(2016) Ulrike Leiter et al.   LANCET ONCOLOGY

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis

(2010) Y. Xing et al.   JNCI-Journal of the National Cancer Institute

Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?

(2010) Ulrike Leiter et al.   MELANOMA RESEARCH